The Dow Jones Index went up by more than 100 points because some companies like Eli Lilly did very well and made a lot of money. Some other companies also had good news that made their stock prices go higher. But, one company called Sunworks had to stop working and its price went down a lot. Read from source...

- The title is misleading and sensationalized. It does not accurately reflect the content of the article or the market performance. A more appropriate title would be "Mixed Results for Stocks; Eli Lilly Beats Earnings Estimates".

1. Buy Agrify (AGFY) for a long-term position based on the recent milestone achievement with PX-30 hydrocarbon extraction system installation in Michigan Facility, which indicates strong growth potential and increasing demand for their products and services in the cannabis extraction industry. The stock has already gained 42% today, showing positive market sentiment. However, there is a high level of volatility and risk associated with AGFY due to its low market capitalization, weak financial position, and lack of profitability. Therefore, only investors with a high risk tolerance and long-term horizon should consider buying AGFY at current levels or on dips.

2. Sell Sunworks (SUNW) for a short-term trade based on the company's recent announcement that it ceased operations and filed voluntary petitions for relief under Chapter 7 of Title 11 of the U.S Code, which means liquidation of its assets and dissolution of the company. This is a clear sign of financial distress and bankruptcy, which makes SUNW an unattractive investment opportunity with no value left to capture. Investors should exit their positions in SUNW as soon as possible and avoid any further losses.

3. Hold BioRestorative Therapies (BRTX) for a speculative position based on the company's promising clinical trial results for its stem cell therapy product, BRTX-100, which has shown significant pain relief and functional improvement in patients with severe lung injuries. However, there is still a lot of uncertainty and risk associated with BRTX due to the lack of commercialization status, regulatory hurdles, and financial constraints. Therefore, investors should only hold BRTX if they are willing to accept a high level of risk and have a long-term outlook. Otherwise, they should consider selling or reducing their exposure to BRTX.